A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin

Chinese Journal of Cancer

Volumn 32, Issue 9, 2013, Pages 520-523

  Cao, Zhi Gang ^a   Zhou, Hong Wei ^a   Peng, Chao Jin ^a   Liu, Mo ^a   Du, Yu ^a   Yang, Qing Ming ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Brentuximab vedotin; Hodgkin lymphoma; Treatment

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CD15 ANTIGEN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; EPSTEIN BARR VIRUS ANTIGEN; ETOPOSIDE; GEMCITABINE; HEMOGLOBIN; INTERLEUKIN 11; NEDAPLATIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT THROMBOPOIETIN; RITUXIMAB; TRANSCRIPTION FACTOR PAX5; VINBLASTINE; VINDESINE;

ADOLESCENT; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; CHINESE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COUGHING; DISEASE ACTIVITY; DISEASE COURSE; FATIGUE; FEMALE; FEVER; HAIR LOSS; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; INGUINAL LYMPH NODE; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MIXED CELLULARITY HODGKIN LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PANCYTOPENIA; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PERIPHERAL NEUROPATHY; REED STERNBERG CELL; SALVAGE THERAPY; SIDE EFFECT; SPLEEN METASTASIS; THROMBOCYTE COUNT;

ADOLESCENT; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; B-CELL-SPECIFIC ACTIVATOR PROTEIN; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; STEM CELL TRANSPLANTATION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84884275926     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10221     Document Type: Article

References (8)

1. Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgin's lymphoma: results of the United Kindom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol, 2005,23:9208-9218.
2. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol, 2008,26:455-462.
3. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica, 2008,93:257-264.
4. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med, 2010,363:1812-1821.
5. Canellos GP. Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma-can they make one of medical oncology's chemotherapy success stories more successful? J Clin Oncol, 2012,30:2171.
6. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol, 2012,30:2183.
7. Helene S. EU Compassionate Use Programmes (CUPs); regulatory framework and points to consider before CUP implementaion. Pharm Med, 2010,24:223-229.
8. Wagner-Johnston ND, Bartlett NL, Cashen A, et al. Progressive multifocal leukoencephalopathy in a patient with Hodgkin's lymphoma treated with brentuximab vedotin. Leuk Lymphoma, 2012,53:2283-2286.